CN106727584A - A kind of pharmaceutical composition for treating osteopathy - Google Patents
A kind of pharmaceutical composition for treating osteopathy Download PDFInfo
- Publication number
- CN106727584A CN106727584A CN201710072181.2A CN201710072181A CN106727584A CN 106727584 A CN106727584 A CN 106727584A CN 201710072181 A CN201710072181 A CN 201710072181A CN 106727584 A CN106727584 A CN 106727584A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- osteopathy
- compound
- pharmaceutically acceptable
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Abstract
The present invention relates to a kind of pharmaceutical composition for treating osteopathy, compound of the described pharmaceutical composition comprising following formula or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for treating osteopathy.
Background technology
Osteopathy include rheumatic arthritis, rheumatoid arthritis, DA, ankylosing spondylitis, cervical spondylopathy,
Lumbar vertebra disease, scapulohumeral periarthritis, osteoproliferation, caput femoris necrosis, cold after delivery etc..Current China generally falls ill various regions, and disability rate is very high, is
Be detrimental to health one of illness the most universal at present.Current treatment by Chinese herbs osteopathy is existed as follows not relative to other therapies
Foot：One is that dosage is not fixed without unified dosage；Two is to use to be required to complicated processing every time, thus takes inconvenience；Three
It is unstable curative effect.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating osteopathy.
In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition for treating osteopathy, the drug regimen
Compound of the thing comprising following formula or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
Preferably, described pharmaceutical composition can be made powder, fine granule, dispersible tablet, capsule or tablet.
The present invention also provides purposes of the compound in the medicine for preparing treatment osteopathy, and the compound has following knot
Structure：
Medicine of the present invention can be used for treating or mitigating osteopathy symptom and related symptoms, obstacle and disease, have
Prestige is developed into new drug clinically.
Specific embodiment
It will be appreciated by those skilled in the art that the concept and specific embodiment disclosed in description above can be easy to
With making an amendment or design the basis of the other embodiment for implementing identical purpose of the invention.What those skilled in the art also will be understood that
It is that these equivalent implementation methods are without departing from the spirit and scope of the present invention illustrated in appended claims.
The sign of the medicine of the present invention of experimental example 1
1H NMR(300MHz,DMSO-d6)δppm0.70-0.82(m,2H)1.04-1.15(m,2H)1.99-2.14(m,
1H) (s, the 1H) 7.85 of 2.26 (s, 3H) 2.36 (d, J=3.01Hz, 3H) 2.87 (t, J=4.43Hz, 4H) 4.05 (s, 3H) 6.55
(d, J=5.09Hz, 1H) 8.07 (s, 1H) 8.51 (s, 1H) 8.94 (s, 1H) 9.62 (s, 1H).
MS(ES+),(M+H)+=439, C21H27FN10。
Therapeutic effect of the medicine of the present invention of experimental example 2 for osteopathy
Knee osteoarthritis model and administration
By cleaning grade (SPF) male Wistar rat (the mouse age 5-6 months, weight 165.0 ± 19.0) be divided into 4 groups：Normally
Control group, model control group, Glucosamine control group, administration group.Every group 10.In addition to Normal group, to remaining each group
The Cys aqueous solution of right knee joint injection 4% Papain enzyme aqueous solution 8 the μ L and 0.04mol/L of rat, and point
Do not strengthened in the 3rd, 7 days, cause osteoarthritis.Start within the 14th day after modeling administration, each group dosage is as follows：Normal group with
Model group, gives physiological saline gavage 1mL/100g body weight；Glucosamine group, Glucosamine 1.5g adds 1500mL physiology salts
Water is configured to suspension, gives gavage 1mL/100g body weight；Administration group, the target compound of 0.015g adds 1500mL physiological saline
Suspension is configured to, gavage 1mL/100g body weight is given.1 times/day, successive administration 30d draws materials for the 49th day after modeling.
ELISA method detection TNF-α
At the 49th day by after death, the blood sampling of row abdominal aorta, by institute blood sampling 3000r/min centrifugation 5min, takes blood at animal
Clearly, -80 DEG C of Refrigerator stores are put to be measured.Concrete operation step presses kit, and (TNF-α ELISA kit is purchased from the enzyme-linked biology in Shanghai
Science and Technology Ltd.) specification carries out.Result see the table below.
Claims (3)
1. a kind of pharmaceutical composition for treating osteopathy, it is characterised in that compound of the described pharmaceutical composition comprising following formula or its
Pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
2. it is according to claim 1 treatment osteopathy pharmaceutical composition, it is characterised in that described pharmaceutical composition can be made
Into powder, fine granule, dispersible tablet, capsule or tablet.
3. compound prepare treatment osteopathy medicine in purposes, it is characterised in that the compound has having structure：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710072181.2A CN106727584A (en) | 2017-02-08 | 2017-02-08 | A kind of pharmaceutical composition for treating osteopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710072181.2A CN106727584A (en) | 2017-02-08 | 2017-02-08 | A kind of pharmaceutical composition for treating osteopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727584A true CN106727584A (en) | 2017-05-31 |
Family
ID=58956896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710072181.2A Withdrawn CN106727584A (en) | 2017-02-08 | 2017-02-08 | A kind of pharmaceutical composition for treating osteopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727584A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111138417A (en) * | 2019-12-18 | 2020-05-12 | 浙江工业大学 | Triazole modified 5-fluoro-2, 4-pyrimidinediamine compound and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903357A (en) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
| CN105294533A (en) * | 2015-12-02 | 2016-02-03 | 宋彤云 | Pharmaceutical composition for treating bone diseases |
| CN106255685A (en) * | 2014-04-28 | 2016-12-21 | Mmv疟疾药物投资公司 | For preventing or treat the Triaminopyrimidine compound of malaria |
-
2017
- 2017-02-08 CN CN201710072181.2A patent/CN106727584A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903357A (en) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
| CN106255685A (en) * | 2014-04-28 | 2016-12-21 | Mmv疟疾药物投资公司 | For preventing or treat the Triaminopyrimidine compound of malaria |
| CN105294533A (en) * | 2015-12-02 | 2016-02-03 | 宋彤云 | Pharmaceutical composition for treating bone diseases |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111138417A (en) * | 2019-12-18 | 2020-05-12 | 浙江工业大学 | Triazole modified 5-fluoro-2, 4-pyrimidinediamine compound and application thereof |
| CN111138417B (en) * | 2019-12-18 | 2021-03-23 | 浙江工业大学 | Triazole modified 5-fluoro-2, 4-pyrimidinediamine compound and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988772B (en) | TCM (Traditional Chinese medicine) composition for treating infantile acute infantile convulsions and preparation method thereof | |
| CN103463624A (en) | Bone joint composite nutrient supplement and preparation method thereof | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN106727584A (en) | A kind of pharmaceutical composition for treating osteopathy | |
| Padhan et al. | Synovial chondromatosis | |
| CN103202894B (en) | Chinese herbal medicine feed additive for preventing and curing infectious serositis of duck | |
| CN101912536B (en) | Medicinal composition for treating rheumatism and rheumatoid disease | |
| CN106822137A (en) | A kind of pharmaceutical composition for treating osteopathy | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| JP2007262103A (en) | Remedy for osteoarthritis | |
| CN106924331A (en) | A kind of application of Aidi preparation in treatment neuroblast tumor medicine is prepared | |
| WO2021212995A1 (en) | Anti-ageing composition, drug and healthcare product comprising same, and application therefor | |
| CN110664994A (en) | Composition for treating osteoarticular diseases | |
| CN105348171B (en) | A kind of pharmaceutical composition treating knee osteoarthritis | |
| CN105919991B (en) | Application of the euparin in preparation medicament for treatment of depression | |
| CN106138085A (en) | A kind of have medicine or the health food increasing bone density effect | |
| CN106822271A (en) | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use | |
| JP4041856B2 (en) | Treatment for osteoarthritis | |
| CN104546730A (en) | Chitosamine hydrochloride pellet preparation and preparation method thereof | |
| CN103961341B (en) | One treats migrainous pharmaceutical composition and application thereof | |
| CN103919794A (en) | Application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance | |
| CN105770042A (en) | Medicine capable of dispelling wind to relieve pain, dispelling cold to remove dampness and strengthening muscles and bones and preparation method of medicine capable of dispelling wind to relieve pain, dispelling cold to remove dampness and strengthening muscles and bones | |
| CN105294533A (en) | Pharmaceutical composition for treating bone diseases | |
| CN102961520B (en) | Pharmaceutical composition for treating arthritis and method for preparing pharmaceutical composition for treating arthritis | |
| CN105125704B (en) | A kind of compositions purposes in the medicine of preparation treatment gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170531 |
|
| WW01 | Invention patent application withdrawn after publication |